Praliciguat is under clinical development by Akebia Therapeutics and currently in Phase I for Focal Segmental Glomerulosclerosis (FSGS). According to GlobalData, Phase I drugs for Focal Segmental Glomerulosclerosis (FSGS) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Praliciguat LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Praliciguat overview

Praliciguat is under development for the treatment of preserved ejection fraction (diastolic heart failure/HFpEF), non-alcoholic steatohepatitis (NASH), fibrotic liver disease and focal segmental glomerulosclerosis (FSGS). The drug candidate is administered orally. It targets soluble guanylate cyclase enzyme. It was also under development for diabetic nephropathy, resistant hypertension in diabetic patients.

Akebia Therapeutics overview

Akebia Therapeutics is a commercial-stage biopharmaceutical company. It develops and commercializes novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. The company’s product portfolio includes vadadustat, a hypoxia-inducible factor (HIF) prolyl hydroxylase that treats dialysis-dependent chronic kidney disease (DD-CKD) and non-dialysis-dependent chronic kidney disease (NDD-CKD); ferric citrate targeting hyperphosphatemia and iron deficiency anemia; AKB-9090 for acute kidney injury and acute respiratory distress syndrome; and AKB-10108, that treats retinopathy of prematurity. It operates through its subsidiaries in the US, Ireland and the UK. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Praliciguat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.